OTCPK:VRSE.F

Stock Analysis Report

Executive Summary

Verisante Technology Inc., a medical device company, engages in commercializing skin cancer detection systems.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Verisante Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

VRSE.F

-1.6%

US Medical Equipment

0.07%

US Market


1 Year Return

0%

VRSE.F

13.8%

US Medical Equipment

8.9%

US Market

Return vs Industry: VRSE.F underperformed the US Medical Equipment industry which returned 13.8% over the past year.

Return vs Market: VRSE.F underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

VRSE.FIndustryMarket
7 Day0%-1.6%0.07%
30 Day0%-4.3%-0.3%
90 Dayn/a-4.3%-1.6%
1 Year0%0%14.7%13.8%11.3%8.9%
3 Year-99.5%-99.5%70.7%65.6%46.3%36.8%
5 Year-99.9%-99.9%117.3%93.5%62.1%44.3%

Price Volatility Vs. Market

How volatile is Verisante Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Verisante Technology undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Verisante Technology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Verisante Technology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of VRSE.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Verisante Technology regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Verisante Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Verisante Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of VRSE.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Verisante Technology's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Verisante Technology performed over the past 5 years?

17.0%

Historical Healthcare annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if VRSE.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare VRSE.F's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if VRSE.F's earnings growth over the past year exceeded the Medical Equipment industry average.


Return on Equity

High ROE: VRSE.F has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: Insufficient data to calculate VRSE.F's Return on Assets to determine if it is higher than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: Insufficient data to calculate VRSE.F's Return on Capital Employed to determine if it has improved over the past 3 years.


Next Steps

Financial Health

How is Verisante Technology's financial position?


In this section we usually analyse Verisante Technology's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Verisante Technology has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of VRSE.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Verisante Technology's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Verisante Technology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VRSE.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VRSE.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VRSE.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VRSE.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VRSE.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Verisante Technology's salary, the management and board of directors tenure and is there insider trading?

5.3yrs

Average board tenure


CEO

Thomas Braun (51yo)

0yrs

Tenure

CA$125,000

Compensation

Mr. Thomas A. Braun, BA, JD, LLB, LLM serves as the Chief Executive Officer and President of Verisante Technology, Inc. (Former Name: T-Ray Science, Inc). Mr. Braun is a Legal Professional of Braun and Com ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Thomas's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.


Board Age and Tenure

5.3yrs

Average Tenure

58yo

Average Age

Experienced Board: VRSE.F's board of directors are considered experienced (5.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Thomas Braun (51yo)

    President

    • Tenure: 0yrs
    • Compensation: CA$125.00k
  • Rizah Bahic

    Executive Officer

    • Tenure: 0yrs
  • Peter Xu

    CFO & Director

    • Tenure: 1.5yrs

Board Members

  • Thomas Braun (51yo)

    President

    • Tenure: 0yrs
    • Compensation: CA$125.00k
  • Wm Werschler

    Member of Clinical Advisory Board

    • Tenure: 5.3yrs
  • Jake Thiessen (76yo)

    Director

    • Tenure: 10.2yrs
  • Harvey Lui (58yo)

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Kenneth Beer

    Member of Clinical Advisory Board

    • Tenure: 5.3yrs
  • Peter Xu

    CFO & Director

    • Tenure: 1.5yrs
  • John Li

    Director

    • Tenure: 1.5yrs

Company Information

Verisante Technology Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Verisante Technology Inc.
  • Ticker: VRSE.F
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$9.861k
  • Shares outstanding: 98.62m
  • Website: https://www.verisante.com

Number of Employees


Location

  • Verisante Technology Inc.
  • 2639 Viking Way
  • Suite 140
  • Richmond
  • British Columbia
  • V6V 3B7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VRSE.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDDec 2009

Biography

Verisante Technology Inc., a medical device company, engages in commercializing skin cancer detection systems. The company’s products comprise Verisante Aura, which helps in the detection of various forms  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:19
End of Day Share Price2019/08/28 00:00
Earnings2017/09/30
Annual Earnings2016/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.